Abstract Objective To study the effect of glucagon-like peptide-1 (GLP-1) combined with Compound Levodopa on Parkinson disease (PD) with diabetes mellitus (DM) patients. Methods A total of 158 PD with DM patients admitted to the First Affiliated Hospital of Hebei North University from January 2018 to June 2020 were selected as the research objects. They were divided into control group (79 cases) and research group (79 cases) according to the random number table method. The control group was given subcutaneous injection of insulin and oral Compound Levodopa Tablets, and the research group was given subcutaneous injection of GLP-1 and oral Compound Levodopa Tablets. The treatment time for both groups was six months. Before and after treatment, the changes of Montreal cognitive assessment scale (MoCA), unified Parkinson disease rating scale (UPDRS)Ⅱ (activity of daily living) and UPDRS Ⅲ (exercise ability) scores in UPDRS were compared. Results During the treatment, two patients in the research group dropped out, and 156 patients were eventually enrolled in the study. After treatment, MoCA score was higher than before treatment, UPDRS Ⅱ and Ⅲ scores were lower than before treatment, and the MoCA score of the research group was higher than that of the control group, and the UPDRS Ⅱ and Ⅲ scores were lower than that of the control group, with statistical significance (P ＜ 0.05). Conclusion GLP-1 combined with Compound Levodopa can not only improve the cognitive function of PD with DM patients, but also improve the quality of life and exercise ability of these patients.
FAN Lei LIU Xingliang LOU Zhan WANG Ying WANG Yuejuan. Effects of glucagon-like peptide-1 combined with Compound Levodopa on Parkinson disease with diabetes mellitus patients[J]. 中国医药导报, 2021, 18(29): 82-85.
